Lilly Will Tap Ambrx’s ReCODE Technology To Develop Metabolic, CNS Candidates
Partnership aims to yield first-in-class or best-in-class therapeutic antibodies and improved variants of native proteins, Ambrx tells “The Pink Sheet” DAILY.
Partnership aims to yield first-in-class or best-in-class therapeutic antibodies and improved variants of native proteins, Ambrx tells “The Pink Sheet” DAILY.